Welcome to our dedicated page for Nuvasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on Nuvasive stock.
NuVasive, Inc. (NASDAQ: NUVA) is a global leader in developing innovative surgical solutions for spine care, specializing in minimally disruptive technologies that improve patient outcomes. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's financial performance, product advancements, and strategic initiatives.
Discover comprehensive coverage of NUVA's latest developments including quarterly earnings reports, new product clearances, strategic partnerships, and regulatory milestones. Our curated collection features official press releases and verified news about the company's expanding portfolio of spinal implants, surgical navigation systems, and biologics solutions.
Stay informed about NuVasive's leadership in transforming spine surgery through key updates on clinical research breakthroughs, global market expansion, and corporate responsibility programs like the NuVasive Spine Foundation®. This resource serves as your primary source for tracking the company's progress in advancing surgical care while maintaining strong financial performance.
Bookmark this page for real-time access to critical updates that impact NUVA's market position and investment potential. Check back regularly for authoritative reporting on one of the medical device sector's most innovative companies.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, announced participation in three upcoming investor conferences. The events are the Citi 2023 Healthcare Services Conference on March 2 in New York City, Cowen's 43rd Annual Health Care Conference on March 8 in Boston, and Barclays Global Healthcare Conference on March 14 in Miami. Management will discuss the recent merger with Globus Medical. Live webcasts of the presentations will be available on the company's Investor Relations page, with replays accessible for 30 days. NuVasive aims to transform surgery with minimally invasive solutions, generating over $1 billion in net sales across 50 countries.
NuVasive, Inc. (NASDAQ: NUVA) announced its financial results for FY 2022, reporting net sales of $1.202 billion, up 5.5% as reported and 8.5% on a constant currency basis. The fourth quarter net sales were $305.4 million, a 1.1% increase year-over-year, despite an $11 million impact from foreign currency fluctuations. GAAP diluted earnings per share for FY 2022 were $0.76, a significant recovery from a loss of $1.24 in the prior year. The company expects 2023 net sales growth of 6%-8%. CEO Chris Barry expressed confidence in upcoming synergies from the merger with Globus Medical.
NuVasive, a leader in spine technology, announced FDA clearance for its Modulus Cervical interbody implant to be used with Attrax Putty. This advancement enhances the C360 portfolio and offers new value to surgeons and hospitals. The 510(k) clearance underlines the company's commitment to providing clinically and economically beneficial solutions. This follows the prior approval of Attrax Putty in December 2021 for thoracolumbar interbody fusion. The integration of advanced materials is expected to positively impact patient outcomes. NuVasive operates in over 50 countries with over $1 billion in net sales.
The merger between Globus Medical (GMED) and NuVasive (NUVA) will form a leading musculoskeletal technology company, enhancing innovation in patient care. Under the all-stock agreement, NuVasive shareholders will receive 0.75 shares of Globus Medical for each share held, implying a price of $57.72 and an equity value of $3.1 billion. The new entity aims to capitalize on a $50 billion market, with combined net sales growth projected at 6-8% for 2023. This transaction is expected to close mid-2023, pending regulatory and shareholder approval.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology, will announce its fourth quarter and full-year 2022 results on February 22, 2023, after market close. A conference call will follow at 1:30 p.m. PT to discuss the financial performance for the year ending December 31, 2022. Participants can access the call via designated dial-in numbers or a live webcast available on the company’s website. NuVasive reported over $1 billion in net sales with operations in more than 50 countries, focusing on minimally invasive surgical solutions.
NuVasive, Inc. (NASDAQ: NUVA), a pioneer in spine technology, announced that CEO Chris Barry will speak at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12, 2023, at 7:30 a.m. PT. A live webcast of the event will be available on the company's Investor Relations page, with a replay accessible for 30 days afterward. NuVasive focuses on transforming spine surgery with minimally invasive solutions, boasting over $1 billion in net sales and operating in more than 50 countries.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology, hosted a virtual event on Nov. 16, 2022, highlighting its latest innovations in spine surgery. The event showcased advancements across its 360 portfolios, emphasizing integration with the Pulse platform and the importance of clinical data. Key surgeons discussed future trends and showcased the benefits of various surgical solutions, including C360, X360, P360, and Complex portfolios. The company continues its commitment to transforming surgery and advancing care, with over $1 billion in net sales.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology, announced that CEO Chris Barry will participate in the Piper Sandler 34th Annual Healthcare Conference in New York on November 30, 2022, at 12:30 p.m. ET. A live webcast of the presentation will be available on the company's Investor Relations page and remain accessible for 30 days. NuVasive specializes in minimally disruptive surgical solutions, achieving over $1 billion in net sales across more than 50 countries. For further details, visit www.nuvasive.com.
NuVasive, Inc. (NASDAQ: NUVA) is reaffirming its role as a diamond sponsor for the Cervical Spine Research Society (CSRS) 50th Annual Meeting from November 16 to 19 in San Diego. The event highlights NuVasive's commitment to advancing cervical technology, particularly with the recent launch of its Reline Cervical solution. CEO Chris Barry emphasizes the importance of their C360 portfolio and its integration with Pulse technology at this influential meeting. Two workshops will showcase pioneering techniques in spinal surgery.
NuVasive reported Q3 2022 net sales of $295.3 million, marking a 9.0% increase year-over-year. Adjusted for constant currency, growth was 12.9%. The company achieved a GAAP operating margin of 7.4% and a non-GAAP operating margin of 13.6%. Non-GAAP diluted EPS rose to $0.54, up from $0.32 in Q3 2021. Full-year guidance now projects net sales growth of 5.5%-6.5% with diluted EPS at $0.50-$0.60. Additionally, a share repurchase program was extended by another year, allowing for $100 million in buybacks.
